Pharmaceuticals - BioReview (Page 12)

Pharmaceuticals

When the Brain Forgets to Stop Eating: What Rhythm's IMCIVREE Approval Means for Hypothalamic Obesity

The FDA approved IMCIVREE (setmelanotide) as the first therapy for acquired hypothalamic obesity on March 19, 2026. Here is what the TRANSCEND trial data mean for patients, the MC4R pathway platform, and the rare disease market.

Pharmaceuticals

The Pill That Could Dethrone the Needle: What Icotyde's Approval Means for Psoriasis Care

For the roughly 125 million people worldwide living with psoriasis, the treatment conversation has long followed a familiar and frustrating arc. Start with topical creams. Cycle through them. Graduate, eventually, to an injectable biologic that requires a needle, a refrigerator, and a willingness to self-administer a shot every few

Pharmaceuticals

The Ibrance Succession: What Pfizer's Atirmociclib Data Reveals About the Next Era of Breast Cancer Treatment

Pfizer's Phase 2 FOURLIGHT-1 data on atirmociclib show a 40% reduction in disease progression risk in CDK4/6 inhibitor-resistant breast cancer, positioning the selective CDK4 inhibitor as a potential successor to Ibrance ahead of its 2027 patent expiry.

Biotechnology

The Pill Race: How Structure Therapeutics Just Changed the Oral GLP-1 Calculus

Structure Therapeutics' aleniglipron showed 15% weight loss in Phase 2 trials, delivering injectable-like efficacy in pill form and reshaping the competitive landscape for oral GLP-1 obesity drugs.

Pharmaceuticals

The $400 Billion Orphan: How Rare Disease Drugs Became Pharma's Most Resilient Franchise

Evaluate's 2026 Orphan Drug Report projects rare disease drug sales will exceed $400 billion by 2032. Behind the headline number lies a more complicated story about FDA volatility, IRA policy shifts, and the structural forces reshaping who wins in rare disease medicine.

Pharmaceuticals

When the Confirmatory Trial Delivers the Verdict: Ipsen's Tazverik Withdrawal and the Accelerated Approval Reckoning

On March 9, 2026, Ipsen announced the immediate voluntary withdrawal of Tazverik (tazemetostat) from all markets worldwide. The decision, triggered by safety signals from the ongoing SYMPHONY-1 confirmatory trial, marks one of the more consequential drug withdrawals in recent oncology history. Not because of the commercial stakes, which were

Markets

Lilly's Employer Gambit: How the GLP-1 Giant Is Rewriting the Rules of Drug Distribution

Eli Lilly's new Employer Connect platform lets workers buy Zepbound at $449/month, bypassing insurers entirely. It is a bold bet that pharma companies can rewrite the rules of drug distribution before compounders and insurers do it for them.

Biotechnology

RNA Medicine Rewrites the Rules: Zorevunersen Becomes First Therapy to Show Disease Modification in Dravet Syndrome

Zorevunersen becomes the first therapy to show disease modification in Dravet syndrome, offering hope for families through improved seizure control and developmental outcomes.

Pharmaceuticals

Johnson & Johnson Achieves FDA Fast Track Milestone: Nipocalimab Advances Toward Potential Breakthrough in Systemic Lupus Erythematosus Treatment

In a significant regulatory achievement that could transform treatment options for millions of patients worldwide, Johnson & Johnson announced on March 3, 2026, that the U.S. Food and Drug Administration has granted Fast Track designation to nipocalimab for the treatment of adults with systemic lupus erythematosus (SLE). This milestone

Biotechnology

Larimar Therapeutics Achieves FDA Breakthrough: First Protein Replacement Therapy for Friedreich's Ataxia Receives Accelerated Development Status

Larimar Therapeutics announced FDA Breakthrough Therapy Designation for nomlabofusp, the first protein replacement therapy for Friedreich's ataxia, opening accelerated pathways for this devastating rare disease.

Pharmaceuticals

Takeda and Protagonist Achieve Major FDA Milestone: First-in-Class Polycythemia Vera Therapy Rusfertide Receives Priority Review

In a significant regulatory achievement that could transform treatment for one of hematology's most challenging conditions, Takeda Pharmaceutical and Protagonist Therapeutics announced on March 2, 2026, that the FDA has accepted their New Drug Application (NDA) and granted Priority Review for rusfertide, a first-in-class hepcidin mimetic

Biotechnology

Neurogene Achieves Historic FDA Breakthrough: First Gene Therapy for Rett Syndrome Receives Accelerated Development Status

In a landmark regulatory achievement that could transform treatment for one of pediatric neurology's most devastating conditions, Neurogene announced on February 27, 2026, that the FDA has granted Breakthrough Therapy Designation to NGN-401, positioning the company's investigational gene therapy as the first potential cure for